Metastatic Pancreatic Cancer Clinical Trial
Official title:
A Phase I/II Study of ABT-888 in Combination With 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients With Metastatic Pancreatic Cancer
People are being asked to participate in this study who have metastatic pancreatic cancer
(cancer that has spread to other parts of the body).
The purpose of this study is to test the efficacy (effectiveness) of a new combination of
drugs, ABT-888 and mFOLFOX-6 (modified 5-Fluorouracil and Oxaliplatin) for patients with
metastatic pancreatic cancer.
ABT-888 inhibits an enzyme called "PARP" which helps to fix damaged DNA. By inhibiting this
enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the mFOLFOX-6, and
will hopefully increase the killing of cancer cells, thus decreasing the tumors in your body.
This is a single arm, open-label Phase I/II study to evaluate the clinical activity of the novel inhibitor of Poly(ADP-ribose) polymerase (PARP), ABT-888 with modified FOLFOX-6 (5-Fluorouracil plus oxaliplatin) in patients with metastatic pancreatic cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04753879 -
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
|
Phase 2 | |
| Completed |
NCT01417000 -
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02975141 -
Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT00761345 -
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT00919282 -
Gemcitabine (GFF) in Patients With Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT01088815 -
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
| Completed |
NCT04133155 -
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
|
||
| Withdrawn |
NCT05251038 -
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04612530 -
PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03602885 -
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
|
N/A | |
| Recruiting |
NCT05442749 -
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03721744 -
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03261947 -
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
|
Phase 2 | |
| Withdrawn |
NCT06017323 -
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 1 | |
| Terminated |
NCT01946646 -
Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT01523457 -
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
| Terminated |
NCT00726037 -
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT00744640 -
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
|
Phase 1/Phase 2 |